Kane Biotech Inc.
KNE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -106.62% | 748.18% | 8.10% | -9.61% | -58.23% |
| Total Depreciation and Amortization | -14.36% | -1.00% | -2.43% | -7.85% | 0.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.27% | -4,902.10% | 133.31% | -195.04% | -29.46% |
| Change in Net Operating Assets | 89.96% | -839.70% | -28.80% | 430.65% | -124.60% |
| Cash from Operations | 75.11% | -117.15% | 48.03% | -163.38% | -287.39% |
| Capital Expenditure | 50.67% | -97.37% | 19.15% | -123.81% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.33% | -9,533.33% | -21.88% | 85.71% | 48.74% |
| Cash from Investing | -100.09% | 85,938.96% | 2.53% | 67.62% | 44.16% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 97.50% | -3,086.69% | -26.54% | -0.20% | -0.26% |
| Issuance of Common Stock | -- | -- | -- | -103.90% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.03% | -241.19% | -18.91% | 3,362.53% | -139.87% |
| Cash from Financing | 101.07% | -1,021.15% | -21.46% | -16.29% | 831.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.70% | -269.88% | 78.84% | -282.12% | 206.11% |
